Form 4: Lifeward CFO Granted 225,000 Stock Options

Lifeward Ltd.'s Chief Financial Officer, Almog Adar, was granted 225,000 stock options under the company's 2025 Incentive Compensation Plan.

Summary

• Almog Adar, Chief Financial Officer of Lifeward Ltd. (LFWD), was granted 225,000 stock options.
• The options were granted under the 2025 Incentive Compensation Plan.
• The grant date for these options is August 13, 2025.
• Each option has an exercise price of $0.717.
• The options relate to Ordinary Shares with a par value of NIS 1.75 per share.
• The options will vest in four equal annual installments, with the first vesting on August 13, 2026.
• Vesting is contingent upon Almog Adar's continued service to the company.
• The options have an expiration date of August 13, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value creation, although it is a routine compensation event rather than a direct indicator of immediate financial performance.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.
• The use of an incentive compensation plan demonstrates a structured approach to executive remuneration.

Negatives

• No immediate negative implications are apparent from this routine executive compensation filing.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued service as of each vesting date, meaning the options could be forfeited if employment ceases before full vesting.

Future Outlook

The grant of stock options with a multi-year vesting schedule indicates a long-term incentive strategy for the Chief Financial Officer, aligning their future performance with the company's long-term success.

Industry Context

The grant of stock options to key executives is a standard practice across various industries, including medical technology, to attract, retain, and incentivize top talent by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• This type of equity grant, specifically stock options with a multi-year vesting schedule, is a common component of executive compensation packages in publicly traded companies, consistent with practices observed in the broader medical device and biotechnology sectors.
• The structure of the grant, including the exercise price and vesting conditions, is typical for incentive-based compensation designed to encourage long-term commitment and performance.

Corporate Governance

Related Party Transactions

• This filing details an equity grant to a company officer, which is a form of related-party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aims to align the Chief Financial Officer's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: While specific to the CFO, such grants are part of a broader compensation philosophy that can impact employee morale and retention strategies.
• Management: Provides a significant long-term incentive for the Chief Financial Officer, contingent on continued service and company performance.

Next Steps

• The options will begin to vest in four equal annual installments starting August 13, 2026.
• The Chief Financial Officer may exercise vested options at the specified exercise price before the expiration date of August 13, 2035.

Key Dates

Keywords

Lifeward, LFWD, Stock Options, Executive Compensation, CFO, Incentive Plan, SEC Form 4, Equity Grant, Insider Transaction